AGA
6
1
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
50%
3 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Safety and Efficacy of VDPHL01 in Males With AGA
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Efficacy and Safety of VDPHL01 in Males With AGA
Safety and Efficacy of VDPHL01 in Males and Females With AGA
A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects
A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)